Abbott Laboratories Pakistan Limited · PSX:ABOT
Abbott Laboratories Pakistan — Investor Presentation (December 2023)
19 slides from Abbott Laboratories Pakistan's investor presentation, Dec 6, 2023
Slide 1: Corporate Briefing Session - 2023
Corporate Briefing Session - 2023 December 6th, 2023
Slide 2: Table of Contents
Table of Contents • Company Overview • Economic Overview • Strategic / Operational Developments • Financial Results for 2022 • Financial Results for Q3-2023 • Q&A
Slide 3: Company Overview
Company Overview Incorporated on July 02, 1948 1962 – Set up Other segments manufacturing Two manufacturing (mainly includes facility in Karachi general health and and listed as public facilities diabetes care) limited company in 1982 Abbott Laboratories (Pakistan) Limited 1,445 Employees Diagnostic
Slide 4: Pakistan – Macro Economic Overview
PAKISTAN – MACRO ECONOMIC OVERVIEW GROSS DOMESTIC PRODUCT GROWTH (REAL GDP%) 6% 6.10% 6.10% 5.77% Growth of Pakistan: 5% 4.56% • GDP growth FY23 - registered 0.29% in FY23, below 4% 4.61% the set target of 5% due to macroeconomic imbalances 4.10% 3.12% supply shocks, and international economic slowd
Slide 5: Fiscal Landscape
FISCAL LANDSCAPE FBR REVENUE COLLECTION Rs bln FBR Tax Collection YOY Growth • FBR revenue collection during FY24-4M was Rs2,748bln up Rs 1,200 40% 28% YoY and was better than target of Rs2,682bln. Revenue 35% target by GoP – Rs9,415bln for FY24 Rs 1,000 30% Rs 800 25% • Increase in direct taxes and
Slide 6: Monetary Landscape & Currency Outlook
MONETARY LANDSCAPE & CURRENCY OUTLOOK CPI & POLICY RATE TREND CPI & POLICY RATE TREND 40% CPI POLICY RATE • Tighten Monetary policy: As per IMF Country Report, Pakistan 35% Monetary Policy needs to remain tight, data driven and proactive. 30% • Policy rate: Expected to reduced by 100bps in next Mone
Slide 7: Strategic / Operational Developments: One-off Price Increase granted to the Pharma industry
STRATEGIC / OPERATIONAL DEVELOPMENTS One-off Price Increase granted to the Pharma industry ❑ The unprecedented devaluation (78% since July 2021), double-digit inflation, sharp increase in the cost of API’s and other inputs (including utilities), had all impacted the viability of firms to continue pr
Slide 8: Financial Results - 2022
Financial Results - 2022
Slide 9: Key Highlights – FY2022
Key Highlights – FY2022 • Overall revenue of the Company increased by 16% reaching Rs. 49.26 bn. Rs. 49.26bn 16% Sales Revenue Sales Growth • Decrease in profitability mainly on account of increase in product cost and rupee devaluation. • Earnings per share was Rs. 30.69 per share (2021: Rs. 60.95 p
Slide 10: Revenue Analysis – FY22
Revenue Analysis – FY22 Annual revenue Segment wise Revenue 50,000 49,258 48,000 (PKR in millions) 16% 46,000 PKR in millions 44,000 42,570 Segment 2022 2021 % change 42,000 40,000 38,000 2021 2022 Pharmaceutical 31,486 27,578 14% ➢ Pharmaceutical sales increased by 14% driven by performance of esta
Slide 11: Segment Gross Profit analysis – FY22
Segment Gross Profit analysis – FY22 Segment GP 18,000 16,075 (9%) Segment-wise GP (PKR in millions) 16,000 14,526 14,000 PKR in million 12,000 10,000 Segment 2022 GP % 2021 GP % 8,000 6,000 4,000 Pharmaceutical 9,336 30% 10,008 36% 2,000 2021 2022 Nutritional 4,488 36% 4,646 46% ➢ Segment profitabi
Slide 12: Financial Results – Q3 2023
Financial Results – Q3 2023
Slide 13: Key Highlights – Q3 2023
Key Highlights – Q3 2023 • Overall revenue of the Company increased by 12% reaching Rs. 41.23 bn. Rs. 41.23bn 12% • Increase in product costs on Sales Revenue Sales Growth account of Rupee devaluation and inflation has affected gross profits during 9M-FY23. • The net profit margin has been impacted
Slide 14: Revenue Analysis – Q3 2023
Revenue Analysis – Q3 2023 Revenue Segment wise Revenue 42,000 41,225 41,000 40,000 12% (PKR in millions) PKR in millions 39,000 38,000 36,951 37,000 Jan - Sep Jan - Sep 36,000 Segment % change 2023 2022 35,000 34,000 2022 2023 Pharmaceutical 27,417 23,282 18% ➢ Pharmaceutical sales increased on acc
Slide 15: Segment Gross Profit analysis – Q3 2023
Segment Gross Profit analysis – Q3 2023 Segment GP 13,000 12,102 Segment-wise GP (PKR in millions) 12,000 11,000 PKR in million 10,000 Jan - Sep Jan - Sep 9,000 Segment 2023 GP % 2022 GP % 8,315 8,000 7,000 Q3 2022 Q3 2023 Pharmaceutical 5,743 21% 7,472 32% ➢ Overall GP margin of the Company decreas
Slide 16: Statement of Profit or Loss – Q3 2023
Statement of Profit or Loss – Q3 2023 Description % Jan - Sep 2023 % Jan - Sep 2022 Variance % Fav / Rupees in millions (Unfav) Sales 100 41,225 100 36,951 4,274 12 Cost of Sales 80 32,910 67 24,850 8,060 32 Gross Profit 20 8,315 33 12,101 (3,786) (31) Selling and Distribution expenses 15 6,192 15 5
Slide 17: Statement of Financial Position – Sep 30, 2023
Statement of Financial Position – Sep 30, 2023 Sep Dec Sep Dec Description Variance Description Variance 2023 2022 2023 2022 Rupees in Millions % Rupees in Millions % Non-current assets Share capital and reserves Property, plant and equipment 12,852 11,989 863 7 Issued, subscribed and paid-up capita
Slide 18: Q&A
Q&A
Slide 19: Thank you
Thank you
Abbott Laboratories (Pakistan) — Investor Presentation (December 2023) on 6ix